poisar

Stocks · News reference

VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

Fiscal.ai

VolitionRx Limited reported its financial results for the third quarter of 2026, highlighting a 157% increase in revenue and a narrowed operating loss compared to the same period in 2025.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — VOLITIONRX LTD (VNRX)

    Filed: 2026-11-12 AccNo: 0001477932-26-006845 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers